Iclusig gets EU reprieve but with 'increased caution'
This article was originally published in Scrip
Executive Summary
The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) has said doctors should continue to use Ariad Pharmaceuticals' leukemia therapy Iclusig – despite sales of the drug being suspended by the company in the US amid safety concerns.